SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
BBH Analysis & Videos »
BBH: Bull or Bear?
The best ETFs for betting on biotech
BBH
-3.28%
in
93 days
Filed under: Newsletters, Stocks to Buy "I'm always looking for market leadership; right now, biotechnology stocks are moving up faster than most anything else," says Ron Rowland. In Money & Markets, he eyes biotech ETFs. "Biotechnology is a fascinating sector, one that's made (and lost) a lot of money for millions of investors in recent decades. That's why, in my opinion, you should become familiar with this industry. "Broadly speaking, it's the application of technology to biological materials - plants, animals and people. <>"Nowadays a lot of biotechnology involves manipulating genetic materia...
|
New Website for Healthcare Investors and Traders
BBH
|
|
|
-45.74%
in
136 days
(closed on 06/26/09)
<> A new website for healthcare investors and traders should be ready to launch by the end of February, which is designed to provide users with more features beyond my current blog format.
The site will feature its own blog, discussion forum, news feeds, videos, stock commentaries (including multiple contributors), and other unique content – including my FDA and Clinical Trial Calendars plus a database that includes hundreds of foreign and U.S.-listed stocks in the healthcare sector which are organized into unique indexes, including:
1....
|
One Year Analysis of Healthcare ETFs
BBH
|
|
|
+4.04%
in
19 days
(closed on 02/10/09)
<> The table at my website link below includes a summary and statistics for the 25 healthcare exchange-traded funds (ETFs) which are currently on the market. The group posted a 23.5% loss over the past year on an equal-weight basis with an average of about $400M in net assets. However, the top eight ETFs by net assets account for 88.5% of all net assets for the entire group of 25, including Healthcare Sector SPDR (XLV), Pharma HOLDRs (PPH), iShares Nasdaq Biotech (IBB), Biotech HOLDRs (BBH), iShares Dow Jones U.S. Healthcare (IYH), iShares S&P Global Healthcare (IXJ), Vanguard Healthcare (VHT...
|
Beyond Active ETFs: Build Your Own
BBH
|
|
|
-3.63%
in
4 days
(closed on 01/22/09)
<> Index Universe reported last week that Grail Partners has requested SEC approval to launch two new exchange-traded funds (ETFs) which are actively managed and do not track an underlying index. The Grail American Beacon Large Cap Value ETF and the Grail American Beacon International Equity ETF would not have any restrictions on trading, but Grail expects to provide more details on target turnover rates for the funds once the managers and investment strategy is in place.
As an alternative investing strategy, why not create your ow...
|
ETF Innovators: 24 New Product Ideas
BBH
|
|
|
+0.00%
in
23 hours
(closed on 01/18/09)
ETF Innovators: 24 New Product Ideas Below are 24 new exchange-traded product (ETP) ideas, which are organized by the following sectors and themes: transports (six), healthcare (11), Non-Healthcare (five), and commodities (two). The 20 stock-based ETF ideas below are structured as semi-active indexes with monthly rebalancing to choose the top rated stocks as active components on an equal-weight basis. <> Most of the ideas represent first-to-market ideas and several such as Air and...
|
Healthcare ETFs Outpace the Market
BBH
|
|
|
-1.23%
in
76 days
(closed on 01/17/09)
<> 
The accompanying table presents an analysis and statistics for the 28 healthcare ETFs listed at the Yahoo! Finance ETF Center. As a group, the healthcare ETFs outpaced the overall market in the past year by more than 10%, posting an average loss of 26.5% compared to a loss of 37.4% for the S&P 500 SPDR ETF (SPY). The best performing healthcare ETF was the Biotech HOLDRs (BBH), thanks to a buyout bid for top holding Genetech (DNA) and solid earnings results this year for the number two position, Amgen (AMGN).
The top three...
|
Amgen Exceeds Expectations, Again
BBH
|
|
|
+6.03%
in
10 days
(closed on 11/01/08)
<> Shares of Amgen (AMGN) have moved into the green in after-hours trading following a late-day Wall Street sell-off that had the Dow tanking by over 500 points. As I wrote earlier today , Amgen was able to both exceed profit and sales expectations for 3Q08 and raise its full-year profit guidance as it had done three months ago when reporting 2Q08 results. Even with the current pop in after-hours to around $54 per share, Amgen is only trading at a PE of 12X on the mid-point of its 2008 profit guidance of $4.45 to $4.55 per share.Amgen poste...
|
An Earnings Encore for Amgen?
BBH
|
|
|
-0.99%
in
5 hours
(closed on 10/22/08)
<> 
I think Amgen (AMGN) will beat consensus estimates for sales and profits again today when it reports after the market close, continuing the same trends as last quarter, including better than expected sales of embattled anemia drugs Aranesp and Epogen. Amgen reported 2Q08 results (see conference call transcript ) that beat consensus analyst estimates and raised its full-year [FY] guidance for earnings and revenue, thanks to much stronger-than-expected sales of its anemia drugs Aranesp and Epogen:
- 2Q08 Revenue +1% at $3.8 bi...
|
Updated FDA Calendar of Decision Dates
BBH
|
|
|
-5.92%
in
18 days
(closed on 10/22/08)
<> <> | Company Name | Ticker | Date | FDA Decision - Mike Havrilla - Updated 10/3/08 | | Ligand Pharma | LGND | 9/19/08 | Promacta NDA | | GlaxoSmithKline | GSK | 9/19/08 | Promacta NDA | | Abbott Labs | ABT | 9/21/08 | Vicodin CR NDA | ...
|
FDA Decision Date Calendar Through January 2009
BBH
|
|
|
-4.41%
in
13 days
(closed on 10/04/08)
<> 
The accompanying table includes a calendar of expected FDA decision dates through the end of January 2009, including nine decisions due by the end of September. Some likely near-term movers on the calendar include Cypress Bioscience (CYPB) + partner Forest Labs (FRX) with a pending decision on milnacipran in the treatment of fibromyalgia slated for the end of October in addition to results from a Phase 3 trial for the drug some time before year end. Also, Discovery Labs (DSCO) is not listed on the calendar, b...
|
A Biotech Bloom in July
BBH
-51.81%
in
471 days
The best performing sector in the past month has been biotech. With investors flocking to safety due to recent financial turmoil and the sharp correction in energy, funds and investors have been warming up to biotech. <>The biotech sector is not without its large risks though and investing here requires more homework and experience than most sectors. The biotech landscape is full of landmines especially with unproven companies with their yet to be proven drugs. The recent backlash the FDA has received due to major flaws in its Vioxx approval and other well publicized failed post approval drugs...
|
Sector analysis: Healthcare
BBH
|
|
|
-47.32%
in
482 days
 Sector analyst Jim Farrish sees potential in the healthcare area, noting, "The best plays are in pharmaceuticals and biotech area."
In his SectorExchange.com service, the advisor assesses the impact of the upcoming election on the industry, as well as the top sector funds for investors seeking exposure to various healthcare sectors. "The outlook for the healthcare sector has been mixed over the last 6-9 months. Part of this is the election and the concerns relative to which part is going to win the election in October. <>"While the impact will not be immediate the market is trading in anticipa...
|
People Bullish on BBH
People Bearish on BBH
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Be the first to start a discussion and earn 2 points.
More Resources
|
About Biotech HOLDRs Trust Biotech HOLDRs Trust
- Answers.com
